--- title: "REG - PureTech Health PLC - Result of AGM" type: "News" locale: "en" url: "https://longbridge.com/en/news/289357330.md" description: "PureTech Health PLC announced the results of its Annual General Meeting held on June 10, 2026. All proposed resolutions were passed by shareholders, including the approval of the 2025 Annual Report and Accounts, the Directors' Remuneration Report, and the re-election or election of several directors such as Sharon Barber-Lui, Michele Holcomb, John LaMattina, Robert Langer, Robert Lyne, and Kiran Mazumdar-Shaw. Additionally, PricewaterhouseCoopers LLP was reappointed as auditors, and authorities were granted for share allotment, pre-emption rights disapplication, and market purchases." datetime: "2026-06-10T16:38:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289357330.md) - [en](https://longbridge.com/en/news/289357330.md) - [zh-HK](https://longbridge.com/zh-HK/news/289357330.md) generator: "portal-rs" --- # REG - PureTech Health PLC - Result of AGM RNS Number : 8399H PureTech Health PLC 10 June 2026 10 June 2026 PureTech Health plc Results of Annual General Meeting The Annual General Meeting of PureTech Health plc ("PureTech" or the "Company") was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 10, 2026. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below. Resolutions For % Against % Withheld Total votes cast 001\. To approve the Company's Annual Report and Accounts for year ended 31 December 2025 148,986,114 99.97 46,392 0.03 10,803 149,032,506 002\. To approve the Directors' Remuneration Report 142,375,459 95.84 6,172,764 4.16 495,086 148,548,223 003\. To re-elect Ms. Sharon Barber-Lui as a Director 143,421,622 96.23 5,617,352 3.77 4,335 149,038,974 004\. To re-elect Dr. Michele Holcomb as a Director 148,415,257 99.58 622,164 0.42 5,888 149,037,421 005\. To re-elect Dr. John LaMattina as a Director 139,575,205 93.65 9,462,210 6.35 5,894 149,037,415 006\. To re-elect Dr. Robert Langer as a Director 142,363,975 95.76 6,298,309 4.24 381,025 148,662,284 007\. To elect Mr. Robert Lyne as a Director 148,496,575 99.64 539,340 0.36 7,394 149,035,915 008\. To re-elect Ms. Kiran Mazumdar-Shaw as a Director 122,266,593 82.04 26,769,322 17.96 7,394 149,035,915 009\. To reappoint PricewaterhouseCoopers LLP as Auditors of the Company 148,776,133 99.83 257,001 0.17 10,175 149,033,134 010\. To authorize the Audit Committee to determine the Auditors' remuneration 148,750,724 99.81 286,702 0.19 5,883 149,037,426 011\. To authorize the allotment of shares 147,843,913 99.61 578,544 0.39 620,852 148,422,457 012\. To disapply pre-emption rights 147,589,781 99.39 905,323 0.61 548,205 148,495,104 013\. To further disapply pre-emption rights for acquisitions and specified capital investments. 146,398,006 98.59 2,096,790 1.41 548,513 148,494,796 014\. To authorize market purchase of own shares 148,852,410 99.90 155,201 0.10 35,698 149,007,611 015\. To authorize general meetings to be called on not less than 14 clear days' notice 148,679,278 99.76 360,501 0.24 3,530 149,039,779 Notes: (1) A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution. (2) As at June 10, 2026, the number of outstanding shares in the Company was 243,418,190 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held. (3) The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company's website https://investors.puretechhealth.com/financials-filings/reports and on the National Storage Mechanism. About PureTech Health PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Contact: PureTech Investor Relations IR@puretechhealth.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RAGAKKBNABKDOAD ### Related Stocks - [PRTC.US](https://longbridge.com/en/quote/PRTC.US.md) ## Related News & Research - [REG - PureTech Health PLC - Holding(s) in Company](https://longbridge.com/en/news/298060388.md) - [Alamar Biosciences director Robert P. Ragusa files initial beneficial ownership statement](https://longbridge.com/en/news/297955252.md) - [First US Bancshares director Robert C. Field reports $54,112 common share purchase](https://longbridge.com/en/news/297932724.md) - [ASP Isotopes COO Robert Ainscow sells 25,000 shares for $97,625](https://longbridge.com/en/news/298084300.md) - [Chrysos Director Robert Adamson Exercises Options to Lift Shareholding](https://longbridge.com/en/news/297984592.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**